The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 3

WOMAC subset and total scores.

	Median score		Median change	Median; % change
	Baseline	Week 12
WOMAC-A
Diclofenac	29.0	15.0	−13.5^*	−48.1^*
	(28.0, 31.0)	(13.0, 17.0)	(−16.0, −11.0)	(−55.2, −40.0)
Wobenzym	31.0	19.0	−12.5^*	−39.7^*
	(30.0, 31.0)	(17.0, 23.0)	(−15.0, −10.0)	(−47.1, −28.0)
Placebo	30.0	21.0	−8.0^*	−28.1^*
	(28.0, 31.0)	(17.0, 25.0)	(−13.0, −5.0)	(−44.8, −16.7)
WOMAC-B
Diclofenac	12.0	6.0	−4.0^*	−43.7^*
	(11.0, 13.0)	(5.0, 7.0)	(−6.0, −3.0)	(−57.1, −21.4)
Wobenzym	11.0	8.0	−4.0^*	−33.3^*
	(10.0, 12.0)	(6.0, 8.0)	(−4.0, −3.0)	(−41.7, −27.3)
Placebo	12.0	8.0	−3.0^*	−26.2^*
	(10.0, 13.0)	(6.0, 10.0)	(−4.0, −2.0)	(−35.7, −16.7)
WOMAC-C
Diclofenac	100.0	53.0	−32.0^*	−36.2^*A
	(93.0, 106.0)	(45.0, 64.0)	(−47.0, −20.0)	(−54.7, −24.0)
Wobenzym	101.5	70.0	−28.5^*	−30.3^*AB
	(96.0, 108.0)	(65.0, 82.0)	(−37.0, −20.0)	(−39.4, −21.1)
Placebo	102.0	75.0	−19.0^*	−19.7^*B
	(92.0, 107.0)	(66.0, 88.0)	(−27.0, −14.0)	(−34.3, −12.7)
WOMAC total
Diclofenac	136.5	74.0	−50.0^*	−38.3^*A
	(133.0, 146.0)	(62.0, 86.0)	(−73.0, −25.0)	(−54.4, −28.8)
Wobenzym	142.5	96.0	−46.5^*	−35.5^*AB
	(136.0, 153.0)	(88.0, 114.0)	(−57.0, −34.0)	(−39.4, −21.1)
Placebo	144.5	101.5	−26.5^*	−17.3^*B
	(129.0, 151.0)	(92.0, 123.0)	(−51.0, −22.0)	(−36.6, −12.5)

All values presented as medians (95% confidence interval).
^*Significantly different from “no change” ( < 0.05).
^A,BTreatment groups with different superscripts differ within the same column ( < 0.05).